Millennium CEO foresight averts Velcade shortage; Cardinal tops Gartner's supply chain list;

> Give high marks to Millennium CEO Deborah Dunsire, who anticipates no shortage of U.S.- and EU-recalled cancer drug Velcade because she ratcheted up volumes with two CMOs as quality concerns grew with supplier Ben Venue Labs. Article

> Cardinal Health has earned top honors in Gartner's 2011 Healthcare Supply Chain list; competition among life sciences manufacturers has "tightened." Report

> GE Healthcare and construction-management company M+W Group have teamed to build biopharma manufacturing capabilities--for vaccines, insulin and biosimilars--in countries aiming to reduce dependence on imports. Article

> European regulators have recommended a third precautionary recall of drugs made by beleaguered Ben Venue Labs--this time, it's for a batch of the antiviral Vistide. Announcement

> QRxPharma has signed DSM Pharmaceutical Products as manufacturer of MoxDuo pain-management capsules. Item

> Advanced BioScience Laboratories has named Intercell vet Claire Zhang to direct GMP development and optimization programs as head of the contractor's downstream bioprocessing group. Item

> Gaymar Industries, purchase by Stryker last year, will eliminate 160 jobs with the closing of two New York plants. Article

> Chinese drugmakers will risk the loss of operating permits if they use prohibited chemicals in drugs or are involved in fake drug production. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.